<HashMap><database>biostudies-literature</database><scores/><additional><submitter>St Thomas N</submitter><funding>NCI NIH HHS</funding><funding>NIH HHS</funding><pagination>76</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11763779</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Cutaneous T-cell lymphoma (CTCL) is a rare T-cell malignancy characterized by inflamed and painful rash-like skin lesions that may affect large portions of the body's surface. Patients experience recurrent infections due to a compromised skin barrier and generalized immunodeficiency resulting from a dominant Th2 immune phenotype of CTCL cells. Given the role of the unfolded protein response (UPR) in normal and malignant T-cell development, we investigated the impact of UPR-inducing drugs on the viability, transcriptional networks, and Th2 phenotype of CTCL. We found that CTCL cells were >5-fold more sensitive to the proteasome inhibitor bortezomib (Btz) and exhibited a distinct signaling and transcriptional response compared to normal CD4+ cells. The CTCL response was dominated by the indu</pubmed_abstract><journal>Biomolecules</journal><pubmed_title>Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma.</pubmed_title><pmcid>PMC11763779</pmcid><funding_grant_id>R01 CA245081</funding_grant_id><funding_grant_id>R01CA245081</funding_grant_id><pubmed_authors>Reyes L</pubmed_authors><pubmed_authors>Golick L</pubmed_authors><pubmed_authors>Dolloff NG</pubmed_authors><pubmed_authors>Christopher BN</pubmed_authors><pubmed_authors>Robinson RM</pubmed_authors><pubmed_authors>Chapman E</pubmed_authors><pubmed_authors>Zhu X</pubmed_authors><pubmed_authors>St Thomas N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma.</name><description>Cutaneous T-cell lymphoma (CTCL) is a rare T-cell malignancy characterized by inflamed and painful rash-like skin lesions that may affect large portions of the body's surface. Patients experience recurrent infections due to a compromised skin barrier and generalized immunodeficiency resulting from a dominant Th2 immune phenotype of CTCL cells. Given the role of the unfolded protein response (UPR) in normal and malignant T-cell development, we investigated the impact of UPR-inducing drugs on the viability, transcriptional networks, and Th2 phenotype of CTCL. We found that CTCL cells were >5-fold more sensitive to the proteasome inhibitor bortezomib (Btz) and exhibited a distinct signaling and transcriptional response compared to normal CD4+ cells. The CTCL response was dominated by the indu</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan</publication><modification>2025-04-18T14:27:55.377Z</modification><creation>2025-04-07T00:38:39.242Z</creation></dates><accession>S-EPMC11763779</accession><cross_references><pubmed>39858470</pubmed><doi>10.3390/biom15010076</doi></cross_references></HashMap>